About Alnara Pharmaceuticals
Alnara Pharmaceuticals is a company based in Cambridge (United States) founded in 2008 was acquired by Lilly in July 2010.. Alnara Pharmaceuticals has raised $55 million across 2 funding rounds from investors including Lilly, Bessemer Venture Partners and Frazier Healthcare Partners. Alnara Pharmaceuticals operates in a competitive market with competitors including Rhythm Pharmaceuticals, MannKind Corp, NGM Biopharmaceuticals, Corcept and ViaCyte, among others.
- Headquarter Cambridge, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Alnara Pharmaceuticals, Inc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Alnara Pharmaceuticals
Alnara Pharmaceuticals has successfully raised a total of $55M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $35 million completed in January 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $35.0M
-
First Round
First Round
(30 Oct 2008)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2010 | Amount | Series B - Alnara Pharmaceuticals | Valuation | MPM Capital | |
| Oct, 2008 | Amount | Series A - Alnara Pharmaceuticals | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Alnara Pharmaceuticals
Alnara Pharmaceuticals has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, Bessemer Venture Partners and Frazier Healthcare Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments and support for entrepreneurs in technology and innovation sectors.
|
Founded Year | Domain | Location | |
|
Healthcare sector private equity investments are managed by the firm.
|
Founded Year | Domain | Location | |
|
Venture capital funding is provided to early-stage life science companies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Alnara Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Alnara Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Alnara Pharmaceuticals Comparisons
Competitors of Alnara Pharmaceuticals
Alnara Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Rhythm Pharmaceuticals, MannKind Corp, NGM Biopharmaceuticals, Corcept and ViaCyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| domain | founded_year | HQ Location |
Developer of small-molecule drugs
|
|
| domain | founded_year | HQ Location |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| domain | founded_year | HQ Location |
Developer of cortisol modulators for the treatment of various diseases
|
|
| domain | founded_year | HQ Location |
Cell therapy for diabetes is developed from stem cells.
|
|
| domain | founded_year | HQ Location |
Developer of therapies for treating nonalcoholic steatohepatitis and other liver and metabolic disorders
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Alnara Pharmaceuticals
When was Alnara Pharmaceuticals founded?
Alnara Pharmaceuticals was founded in 2008.
Where is Alnara Pharmaceuticals located?
Alnara Pharmaceuticals is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Alnara Pharmaceuticals a funded company?
Alnara Pharmaceuticals is a funded company, having raised a total of $55M across 2 funding rounds to date. The company's 1st funding round was a Series A of $20M, raised on Oct 30, 2008.
What does Alnara Pharmaceuticals do?
Alnara Pharmaceuticals was established in 2008 in Cambridge, United States, within the biotechnology sector. Novel protein therapeutics are developed for metabolic diseases, with operations centered on oral delivery to the gastrointestinal tract to bypass bloodstream absorption. The lead product, liprotamase, addresses cystic fibrosis and was licensed worldwide from the Cystic Fibrosis Foundation for development and commercialization. Acquisition by Eli Lilly took place in 2010 for 380 million USD.
Who are the top competitors of Alnara Pharmaceuticals?
Alnara Pharmaceuticals's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Corcept.
Who are Alnara Pharmaceuticals's investors?
Alnara Pharmaceuticals has 5 investors. Key investors include Lilly, Bessemer Venture Partners, Frazier Healthcare Partners, Turmeric Acquisition Corp, and Third Rock Ventures.